足三里、肾俞穴位埋线对类风湿关节炎血清TNF-a、IL-6的影响  被引量:10

Influence of Zusanli and Shenshu Catgut-embedding Therapy on Serum TNF-a and IL-6 of Patients with Rheumatoid Arthritis

在线阅读下载全文

作  者:阮崇洁[1] 马志毅[1] 李勇[1] 

机构地区:[1]武汉市中医医院,湖北武汉430014

出  处:《针灸临床杂志》2016年第3期43-45,共3页Journal of Clinical Acupuncture and Moxibustion

基  金:湖北省自然基金课题;编号:ZRY0730

摘  要:目的:观察穴位埋线治疗类风湿关节炎(RA)对血清TNF-a、IL-6的影响,探讨穴位埋线治疗RA的可能机制。方法:采用随机数字表法将患者分为观察组和对照组,每组各30例。对照组口服来氟米特片(每次20 mg,每天1次),疗程3个月;观察组在对照组口服药物的基础上加用足三里、肾俞穴位埋线,每15日埋线1次,共治疗6次,总疗程3个月。3个月后观察两组血清TNF-a、IL-6的变化并进行比较。结果:观察组治疗前后血清TNF-a、IL-6水平显著降低,差异具有统计学意义(P<0.05);两组治疗后比较,观察组血清TNF-a、IL-6水平低于对照组,差异具有统计学意义(P<0.05)。结论:穴位埋线治疗类风湿关节炎能够明显降低血清TNF-a、IL-6水平,表明穴位埋线治疗类风湿关节炎的机制可能是通过抑制血清TNF-a、IL-6生成来实现的。Objective: To observe the influence of acupoint catgut- embedding therapy on serum TNF- a and IL- 6 of patients with rheumatoid arthritis( RA),as well as to discuss the possible mechanism of therapy.Methods: A total of 60 patients with RA were randomly assigned into two groups. 30 cases in the control group were only medicated by leflunomide( 20 mg qd) for three months,and 30 cases in the intervention group were given leflunomide and acupoint catgut- embedding with Zusanli( ST 36) and Shenshu( BL 23),twice a month for three months. After three months,changes of serum TNF- a and IL- 6 were compared between two groups.Results: The levels of serum TNF- a and IL- 6 were significantly reduced in both groups( P〈 0. 05). The levels of serum TNF- a and IL- 6 after the therapy in the intervention group were significantly lower than those in the control group( P〈 0. 05). Conclusion: It is effective to reduce the serum TNF- a and IL- 6 of patients with RA by the acupoint catgut- embedding therapy,which indicates that the mechanism of the therapy on RA is probably to suppress the generation of serum TNF- a and IL- 6.

关 键 词:穴位埋线 类风湿关节炎 TNF-A IL-6 

分 类 号:R246.2[医药卫生—针灸推拿学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象